# info@crystallizationsummit.com

Category : 2024

Dr. Lotfi Derdour, GlaxoSmithKline

Lotfi completed his Bachelor’s degree in Chemical Engineering as top student in 1993 from University of Science and Technology, Oran, Algeria. He then obtained his master’s in Industrial Chemistry...

Solid Form Design and Selection Utilizing Combined Experimental and Computational Techniques

By Dr. Rajni Miglani Bhardwaj, Ph.D. Associate Research Fellow, Pfizer Commercial solid form selection is one of the key milestones during drug product development. It is also critical as...

Dr. Rajni Miglani Bhardwaj, Pfizer

Rajni Miglani Bhardwaj is Associate Research Fellow at Pfizer. She completed her undergraduation in pharmacy at MD University, India (2003), masters in medicinal chemistry at NIPER, India (2005) and...

Computer-aided solid form design: Current challenges, future opportunities

By Dr. Susan M. Reutzel-Edens, Ph.D. FRSC President, SuRE Pharma Consulting, LLC Drug product design generally begins with identifying, oftentimes through experimental crystallization screening, solid forms in which to...

Dr. Susan M. Reutzel-Edens, SuRE Pharma Consulting, LLC

Dr. Susan M. Reutzel-Edens, President of SuRE Pharma Consulting, LLC, earned her Ph.D. in Chemistry at the University of Minnesota under the direction of the late Professor Margaret C....

Crystal structure prediction for realistic pharmaceutical targets with AIMNet2 neural network potential

By Dr. Olexandr Isayev, Ph.D. Associate Professor, Carnegie Mellon University   Machine learned interatomic potentials (MLIPs) are reshaping computational chemistry practices because of their ability to drastically exceed the...

Prof. Olexandr Isayev, Carneige Mellon University

Olexandr Isayev is an Associate Professor at the Department of Chemistry at Carnegie Mellon University. In 2008, Olexandr received his Ph.D. in computational chemistry. He was a Postdoctoral Research Fellow at Case...

Fast-tracking Pharmaceutical Process Optimization with Small Data and Machine Learning

By Dr. Daniela Blanco, Ph.D., CEO and Co-Founder, Sunthetics Pharmaceutical crystallizations, as well as process and product development present significant challenges in terms of cost, efficiency, and sustainability. Harnessing...

Use of automation, dynamic image analysis, and process analytical technologies to enable data rich particle engineering efforts at the Drug Substance / Drug Product interface: A case study using Lovastatin

By Dr. Jeremy M. Merritt, Ph.D. Senior director and Group leader, Eli Lilly & Co. Automation plays a vital role in reducing development time in the pharmaceutical industry, both...

Dr. Jeremy M. Merritt, Eli Lilly & Co.

Jeremy M. Merritt (merrittje@lilly.com) is currently a Senior director and group leader at Eli Lilly and Co. in the synthetic molecule design and development organization (SMDD).  He joined Lilly...

RSS
Follow by Email
LinkedIn
Share